Regeneron Pharmaceuticals, Inc. (REGN) Earns “Buy” Rating from Citigroup Inc.
Citigroup Inc. reiterated their buy rating on shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in a research note released on Friday. Citigroup Inc. currently has a $420.00 price objective on the biopharmaceutical company’s stock.
Several other equities analysts have also recently issued reports on the company. RBC Capital Markets set a $626.00 price objective on Regeneron Pharmaceuticals and gave the company a buy rating in a report on Monday, December 5th. Leerink Swann set a $513.00 price objective on Regeneron Pharmaceuticals and gave the company a buy rating in a report on Tuesday, October 25th. Roth Capital set a $520.00 price objective on Regeneron Pharmaceuticals and gave the company a buy rating in a report on Friday, October 28th. Vetr raised Regeneron Pharmaceuticals to a buy rating in a report on Monday, November 21st. Finally, Canaccord Genuity set a $450.00 price objective on Regeneron Pharmaceuticals and gave the company a hold rating in a report on Friday, February 3rd. Thirteen equities research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of Buy and a consensus price target of $447.16.
Regeneron Pharmaceuticals (NASDAQ:REGN) traded down 2.86% during trading on Friday, reaching $373.02. The company’s stock had a trading volume of 1,277,299 shares. The firm has a market capitalization of $39.34 billion, a P/E ratio of 48.45 and a beta of 1.44. Regeneron Pharmaceuticals has a one year low of $325.35 and a one year high of $452.96. The stock has a 50-day moving average of $363.17 and a 200 day moving average of $385.47.
Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Thursday, February 9th. The biopharmaceutical company reported $3.04 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $3.03 by $0.01. The business earned $1.23 billion during the quarter, compared to analysts’ expectations of $1.30 billion. Regeneron Pharmaceuticals had a return on equity of 22.51% and a net margin of 18.10%. The company’s revenue for the quarter was up 11.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.83 EPS. On average, equities research analysts predict that Regeneron Pharmaceuticals will post $13.17 EPS for the current fiscal year.
This article was posted by Watch List News and is the property of of Watch List News. If you are accessing this article on another site, it was illegally copied and republished in violation of US and international trademark and copyright law. The original version of this article can be accessed at http://www.watchlistnews.com/regeneron-pharmaceuticals-inc-regn-earns-buy-rating-from-citigroup-inc/1121099.html.
In other news, major shareholder Sanofi purchased 87,298 shares of the stock in a transaction dated Wednesday, January 11th. The stock was acquired at an average cost of $369.71 per share, for a total transaction of $32,274,943.58. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Charles A. Baker sold 3,000 shares of the firm’s stock in a transaction on Monday, December 12th. The stock was sold at an average price of $392.02, for a total value of $1,176,060.00. Following the transaction, the director now owns 12,000 shares of the company’s stock, valued at $4,704,240. The disclosure for this sale can be found here. Corporate insiders own 10.40% of the company’s stock.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in REGN. Alpha Windward LLC raised its position in Regeneron Pharmaceuticals by 11.6% in the third quarter. Alpha Windward LLC now owns 326 shares of the biopharmaceutical company’s stock valued at $131,000 after buying an additional 34 shares in the last quarter. IFP Advisors Inc raised its position in Regeneron Pharmaceuticals by 32.3% in the second quarter. IFP Advisors Inc now owns 328 shares of the biopharmaceutical company’s stock valued at $115,000 after buying an additional 80 shares in the last quarter. NEXT Financial Group Inc raised its position in Regeneron Pharmaceuticals by 46.9% in the third quarter. NEXT Financial Group Inc now owns 360 shares of the biopharmaceutical company’s stock valued at $145,000 after buying an additional 115 shares in the last quarter. Live Your Vision LLC purchased a new position in Regeneron Pharmaceuticals during the third quarter valued at approximately $157,000. Finally, Global X Management Co. LLC raised its position in Regeneron Pharmaceuticals by 212.7% in the third quarter. Global X Management Co. LLC now owns 419 shares of the biopharmaceutical company’s stock valued at $168,000 after buying an additional 285 shares in the last quarter. Institutional investors and hedge funds own 68.83% of the company’s stock.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company’s segment includes activities related to the discovery, development and commercialization of pharmaceutical products for the treatment of serious medical conditions.
Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.